The antiretroviral Descovy was approved for use as PrEP to reduce the risk of HIV infection among at-risk adults and adolescents given trial results that showed comparable efficacy to Truvada, the first drug approved for PrEP. FDA approval, however, excludes Descovy for PrEP for receptive vaginal intercourse as its efficacy in that population has not been evaluated. Gilead has a post marketing commitment to conduct such a trial.
With the October 3, 2019 approval by the Food and Drug Administration, there are now two PrEP drugs: Truvada and now Descovy. Read more from the sources:
- FDA's October 3 press release, FDA approves second drug to prevent HIV infection as part of ongoing efforts to end the HIV epidemic
- FDA's summary of the Descovy's product labeling changes, DESCOVY: New Indication for PrEP